Weizmann Institute, Rehovot | Israel
Our group identifies gene mutations that play a role in melanoma progression aiming to delineate protein target combinations to achieve disease control. We identify melanoma neo-antigens using genetic and HLA-peptidomics methods and characterize the immune response to these neo-antigens. We have further developed relevant mouse models to investigate the role tumor heterogeneity plays in the tumor immune response.
Keywords: Cutaneous melanoma / functional genomics / immuno-genomics / neo-antigens / HLA peptidomics / intra-tumor heterogeneity / driver genes / T cell receptors / immunotherapy / cancer vaccines